NOTE: This order is nonprecedential. United States Court of Appeals
for the Federal Circuit
In Re ENTRESTO (SACUBITRIL/VALSARTAN)
NOVARTIS PHARMACEUTICALS CORPORATION,
Plaintiff-Appellant
v.
TORRENT PHARMA INC., TORRENT
PHARMACEUTICALS LTD.
Defendants-Appellees
NOVARTIS PHARMACEUTICALS CORPORATION,
Plaintiff-Appellant
v.
ALEMBIC PHARMACEUTICALS LIMITED,
ALEMBIC PHARMACEUTICALS INC.,
Defendants
NOVARTIS PHARMACEUTICALS CORPORATION,
Plaintiff-Appellant
v.
2HETERO USA, INC., HETERO LABS LIMITED,
HETERO LABS LIMITED UNIT-III, MSN
PHARMACEUTICALS, INC., MSN LABORATORIES PRIVATE LTD., MSN LIFE SCIENCES PRIVATE
LTD.,
Defendants-Appellees
2023-2218, 2023-2219, 2023-2220, 2023-2221
Appeals from the United States District Court for the District of Delaware in Nos. 1:19-cv-01979-RGA, 1:19-cv-02021-RGA, 1:19-cv-02053-RGA, and 1:20-md-02930-RGA, Judge Richard G. Andrews.
NOVARTIS PHARMACEUTICALS CORPORATION,
Plaintiff-Appellant
v.
MYLAN PHARMACEUTICALS INC.,
Defendant-Appellee
2023-2260
Appeal from the United States District Court for the Northern District of West Virginia in No. 1:19-cv-00201-TSK, Chief Judge Thomas S. Kleeh.
O R D E R
Novartis Pharmaceuticals Corporation and Mylan Pharmaceuticals Inc. submit a joint stipulation to dismiss3 Appeal No. 2023-2260 pursuant to Rule 42(b)(1) of the Federal Rules of Appellate Procedure, agreeing that each bear its own costs with respect to Appeal No. 2023-2260. Upon consideration thereof, IT IS ORDERED THAT:
(1) Appeal No. 2023-2260 is deconsolidated from Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221, and Appeal No. 2023-2260 is dismissed. Each side shall bear its own costs regarding Appeal No. 2023-2260. (2) The stay in Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221 is lifted. (3) The Clerk of Court shall transmit a copy of this order to the merits panel assigned to Appeal Nos. 2023-2218, 2023-2219, 2023-2220, and 2023-2221.
FOR THE COURT
March 6, 2024 Date
ISSUED AS A MANDATE (as to Appeal No. 2023-2260 only): March 6, 2024